Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DTG/3TC vs BIC/TAF/FTC in Treatment-Naive HIV (TEOTL)
NCT07031063Phase 4Recruiting
- Sponsor
- Instituto Mexicano del Seguro Social
- Start
- Apr 2025
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 4 trial of dolutegravir + lamivudine in human immunodeficiency virus infection (HIV), sponsored by Instituto Mexicano del Seguro Social. Started Apr 2025; status: recruiting.
02
Drugs
dolutegravir + lamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07031063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07031063.